stockrow
Friday 6 November 2026
Export ZLAB’s income statement to Excel — free account
Zai Lab Limited Unsponsored ADR
ZLAB Healthcare Biotechnology
Zai Lab Limited Unsponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $460.2 million, up 15.3% from fiscal 2024.
- Revenue
- −6.79%
- EPS
- −24.3%
- Free cash flow
- −95.5%
- Total debt
- +24.3%
Quarter to September 2026, against a year earlier
25.47
2.87
+12.70%
Follow ZLAB
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 5 Nov | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
4.20 | 4.60 | 4.72 | 6.66 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(74.25) | (174.87) | (33.47) | (50.84) | |
P/B ratio |
2.70 | 3.15 | 3.50 | 5.22 | |
Price to Tangible BV |
3.04 | 3.57 | 4.09 | 6.20 | |
EV/Sales |
2.93 | 3.39 | 3.65 | 5.61 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(8.93) | (15.20) | (12.32) | (15.56) | |
EV/FCF |
(8.21) | (11.57) | (10.11) | (12.58) | |
Quick Ratio |
2.15 | 2.07 | 1.84 | 0.15 | |
Current Ratio |
2.45 | 2.40 | 2.13 | 2.04 | |
Net Debt/EBITDA |
8.75 | 8.19 | 6.50 | 0.00 | |
Debt/Assets |
17.45% | 19.51% | 22.15% | 24.65% | |
Debt/Equity |
0.29 | 0.32 | 0.39 | 0.45 | |
Asset Turnover |
0.39 | 0.40 | 0.40 | 0.40 | |
Operating CF/Net income |
0.52 | 0.23 | 1.25 | 1.25 | |
Capex/Depreciation |
(0.50) | (8.74) | (0.52) | 0.00 | |
Interest Coverage |
(51.03) | (42.39) | (48.20) | (39.94) | |
Research and Development Expense of Revenue |
48.30% | 65.85% | 58.10% | 46.03% | |
Selling, General and Administrative Expense of Revenue |
57.24% | 65.32% | 68.55% | 64.76% | |
Intangible Assets out of Total Assets |
0.07 | 0.07 | 0.08 | 0.00 | |
Share Based Compensation of Revenue |
12.46% | 13.58% | 11.23% | 10.16% | |
Graham Net Nets |
0.29 | 0.25 | 0.21 | 0.14 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(9.13%) | (8.61%) | (9.00%) | (6.49%) | |
Free Cash Flow Yield |
(8.49%) | (6.37%) | (7.65%) | (6.69%) | |
Revenue per Share |
1.16 | 0.90 | 0.95 | 0.00 | |
Operating CF per Share |
(0.24) | (0.11) | (0.57) | 0.00 | |
Capex per Share |
(0.01) | (0.20) | (0.01) | 0.00 | |
Free Cash Flow per Share |
(0.25) | (0.31) | (0.58) | 0.00 | |
Cash per Share |
7.21 | 6.87 | 6.42 | — | |
Shareholders Equity per Share |
6.53 | 5.98 | 5.43 | 0.00 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
6.53 | 5.98 | 5.43 | 0.00 | |
Free Cash Flow |
(27.32) | (34.20) | (64.82) | (70.55) | |
Working Capital |
603.12 | 551.75 | 485.45 | 440.15 | |
Capital Expenditures |
(1.30) | (22.29) | (1.42) | (12.68) | |
Net Current Asset Value |
562.40 | 510.97 | 446.28 | 403.78 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.22 | 0.01 | 0.12 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
95.65 | 65.31 | 79.05 | 75.34 | |
Average Payables |
121.26 | 114.59 | 122.02 | 109.98 | |
Average Inventory |
57.31 | 69.51 | 76.30 | 76.21 | |
Average Assets |
1,179.07 | 1,134.53 | 1,119.45 | 1,091.42 | |
Average Common Equity |
778.20 | 736.37 | 699.39 | 661.61 |
Columns are period end dates · fundamentals updated 5 Nov 2026